Patient-reported barriers and facilitators to antiretroviral adherence in sub-Saharan Africa

Natasha Croomea, Monisha Ahluwaliab, Lyndsay D. Hughesb,∗ and Melanie Abasa,∗

Objective: The aim of this study was to identify the range and frequency of patient-reported barriers and facilitators to antiretroviral treatment (ART) adherence in sub-Saharan Africa (SSA).

Design: Studies from 2005 to 2016 were identified by searching 10 electronic databases and through additional hand and web-searching.

Methods: Inclusion criteria were HIV-positive adults taking ART based in any SSA country, qualitative study or quantitative survey and included at least one patient-reported barrier or facilitator to ART adherence. Exclusion criteria were only including data from treatment-naive patients initiating ART, only single-dose treatment, participants residing outside of SSA and reviews.

Results: After screening 11,283 records, 154 studies (161 papers) were included in this review. Forty-three barriers and 30 facilitators were reported across 24 SSA countries. The most frequently identified barriers across studies were forgetting (n = 76), lack of access to adequate food (n = 72), stigma and discrimination (n = 68), side effects (n = 67) and being outside the house or travelling (n = 60). The most frequently identified facilitators across studies were social support (n = 60), reminders (n = 55), feeling better or healthier after taking ART (n = 35), disclosing their HIV status (n = 26) and having a good relationship with a health provider (n = 22).

Conclusion: This review addresses the gap in knowledge by collating all the patient-reported barriers and facilitators to ART adherence in SSA. Current barriers measures need to be adapted or new tools developed to include the wide variety of factors identified. The factors that have the greatest impact need to be isolated so interventions are developed that reduce the barriers and enhance the facilitators.

Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc.

Keywords: Africa South of the Sahara, AIDS, antiretroviral therapy, HIV, medication adherence

Introduction

Nearly 25 million people, 70% of all those living with HIV globally, live in countries in sub-Saharan Africa (SSA) [1]. HIV is a debilitating disease; however, antiretroviral treatment (ART) helps promote effective viral suppression, reduces the risk of transmission and prevents death [2,3]. To ensure positive treatment outcomes, high levels of ART adherence (80–95%) are necessary depending on the regime potency [4–6];
however, a meta-analysis [7] indicated that 23% of Africans were achieving less than 80% adherence, potentially impacting on prognosis.

Mills et al. [3] conducted a systematic review in 2005 of patient-reported barriers and facilitators to ART adherence globally. This review identified important barriers, in both high-income countries (HIC) and low and middle-income countries (LMIC), which included substance abuse, forgetfulness, pill burden, fear of disclosure, falling asleep, decreased quality of life, access to medication, being suspicious of the treatment, work and family responsibilities and complicated regimens; however, only 12 (14.3%) of the studies included were conducted in LMIC of which only five were in SSA. ART availability in SSA has improved since this review was conducted, with 1.3 million patients receiving ART treatment in 2006; a 10-fold increase on patients with access 3 years earlier [8]. The lack of treatment availability would have impacted the number of studies being conducted in this region, which has steadily increased over the past decade.

No facilitators were identified by Mills et al. in LMIC [3]; however, important facilitators were identified, including seeing positive effects of medication, accepting their HIV status, using reminders, having a simple regimen, sense of self-worth and understanding the need for strict adherence. Although some similarities were found between different settings and countries, the review urged the need to determine the patient-important factors for adherence in LMIC [3] due to the number of people living with HIV in these areas and the unique psycho-socio-political environments.

In the past decade, there has been a shift in simply identifying and reporting rates of nonadherence and an increased focus to identifying and addressing barriers and facilitators to ART adherence in LMIC, in particular in SSA [9–11]; therefore, this systematic review is a critical update. The review identifies adult patient-reported barriers and facilitators to ART adherence in SSA from 2005 to 2016 in studies with qualitative and quantitative methodology.

Materials and methods

Search strategy
The review was conducted in-line with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines (PRISMA) [12]. N.C. performed searches on 10 databases on 24 May 2016: Cochrane Library, MEDLINE (OVID), PsycINFO (OVID), PsycARTICLES (OVID), EMBASE (OVID), Global Health (OVID), CINAHL (EBSCO), International Bibliography of the Social Science (IBSS; Proquest), Applied Social Sciences Index and Abstracts (AIDIA; Proquest) and African Index Medicus (AIM; WHO). Search terms were varied to adapt to the different requirements of the different databases. The search included terms related to HIV, ART, SSA countries and adherence (see supplementary material for full example of search strategy, http://links.lww.com/QAD/B44).

All databases were searched from 2005 to 24 May 2016 to investigate the research published since the review by Mills et al. [3]. All records were downloaded into ENDNOTE (X7.4).

Hand-searching, web-searching and forward citation searching were conducted to find other relevant published and unpublished studies. Abstracts from the following international conferences were searched: International AIDS Society (IAS; 2005–2015), Conference on Retroviruses and Opportunistic Infections (CROI; 2014, 2016), AIDS Impact (2009–2015) and International AIDS Conference (2006–2014). For all potentially relevant abstracts, if no published article was found, the authors were contacted for more details if possible. Reference lists of included articles and systematic reviews were searched. Searches in Google Scholar were conducted using search terms such as ‘adherence’, ‘HIV’ and ‘Sub-Saharan Africa’. Forward tracking of the review by Mills et al. [3] was also performed in the Web of Science database.

Study selection
N.C. reviewed all the titles and abstracts of each record to assess potential relevance and M.Ah. examined a random sample (10%) and a concordance rate was measured. Acceptable concordance was predefined as agreement on at least 90%, which is the same as other health reviews [13,14]. N.C. reviewed the full text for any potentially relevant studies to assess eligibility. Eligible studies met the following criteria: based in SSA, original research, any language, qualitative study or quantitative survey and included an adult patient-reported barrier or facilitator to ART adherence. Studies were excluded if they only focused on initiation to ART in treatment-naïve participants, only utilized a single dose of ART treatment, for example prophylaxis, only focused on Africans living in a non-SSA country or were only reviews.

Quality assessment
N.C. completed quality assessment for all included studies. M.Ah. assessed a random sample of 30 (15 qualitative and 15 quantitative). The RATS (Relevance, Appropriateness, Transparency, Soundness) measure [15] was used to assess the qualitative studies and a measure developed by Hawker et al. [16] was used to assess the quantitative studies (see supplementary material for further details, http://links.lww.com/QAD/B44).
Data extraction
N.C. extracted all the data into a predesigned Excel spreadsheet that was double checked for accuracy. After an initial read of all qualitative papers, a list of all key barriers and facilitators were identified and were combined into themes. N.C., L.D.H. and M.Ab. discussed the themes and any disputes were resolved (see supplementary material for further details on extraction, http://links.lww.com/QAD/B44). Due to the considerable heterogeneity of the studies, a meta-analysis was not suitable.

Results
A total of 161 papers involving 154 studies were identified for inclusion. The search of the 10 databases provided a total of 11283 citations (see Fig. 1). After adjusting for

---

**Fig. 1. Flowchart.**
Duplicates, 6065 citations remained. Of these, 5266 citations were excluded after reviewing the title and abstracts. The majority of these were excluded (4943; 93.9%) because they were not related to HIV or adherence. The remaining 323 citations (6.1%) were excluded based upon other criteria.

The full text of the remaining 799 potentially relevant citations were searched for; however, 12 (1.5%) could not be retrieved. The full texts of the remaining 787 papers were examined in more detail. Fourteen were excluded (1.8%) because the search had identified both published and unpublished formats of the same studies; therefore, the published versions were retained. A further 632 papers (80.3%) were excluded based upon inclusion and exclusion criteria. From the 141 relevant papers (17.9%) identified, 134 relevant studies were included. From the additional searching, a further 20 studies were identified that met the criteria for inclusion. An acceptable concordance of 91.0% was achieved between N.C. and M.Ah. for inclusion of studies.

Overall, 154 studies were eligible of which 83 were qualitative [17–99], 67 were quantitative [100–166] and four were mixed [167–170], which included at least one patient-reported barrier or facilitator in both the qualitative and quantitative studies included in the paper. Three studies were published in French [116,137,149] and a fluent French speaker was utilized to extract the data and translate into English. The remaining studies were published in English.

Description of studies

A total of 37 175 HIV-positive participants were included across all 154 quantitative and qualitative studies of which 36 476 were prescribed ART. Within the 87 quantitative studies, 3247 HIV-positive participants were included of whom 2824 were prescribed ART. Within the 71 qualitative studies, 33 928 HIV-positive participants were included of whom 33 652 were prescribed ART (see supplementary material for further details, http://links.lww.com/QAD/B44).

Studies were conducted in 24 countries in SSA with six studies including more than one country [45,64,84,95,124,130]. More than half the studies (59.7%) were conducted across South Africa, Uganda, Ethiopia and Kenya.

Just over half of the qualitative studies conducted semi-structured in-depth interviews (IDIs) [49; 56.3%] [17,20–22,26,27,29,32–37,39–43,45–47,49,51,54–60, 62,63,65–67,69–71,78,81,84,85,87–90,95–97,165] with their HIV-positive participants. Eighteen studies (20.7%) used focus group discussions (FGDs) [19,23–25,28,50, 53,61,68,73,74,76,77,82,94,98,167,169], 16 used both IDIs and FGDs (18.4%) [18,30,31,38,44,52,64,72,75,79, 83,86,92,93,99,170], one used free attitude interviews (FAIs) and FGDs (1.1%) [80], one used group sessions without more detail [168], one used IDIs and life history and illness narratives [48] and one used digital stories [91].

The majority of the quantitative surveys (54; 76.1%) were administered by an interviewer [100,102,104–109, 112,113,115–117,119,121–124,128–130,133–137,139, 141–150,152–166,168,169], five (7.0%) were self-administered [125,126,132,140,151], one (1.4%) used an audio computer-assisted self-interview [110] and the remaining studies (11; 15.5%) did not specify or it was not clear how the survey was administered [101,103,111,114, 118,120,127,131,138,167,170]. No studies indicated clearly that there was a free response option for participants to report the barriers they experienced (for further description on the studies see the supplementary material, http://links.lww.com/QAD/B44).

Quality assessment

The qualitative studies showed overall high quality, with 98.9% of studies including all RATS items related to relevance of study question, 72.4% including the item related to appropriateness of qualitative method and 83.5% including all items related to soundness of interpretive approach, with the exception of poor transparency of the procedure (only 55.0% of studies included all items). In particular, studies required more information regarding recruitment (only 23.0% of studies included this), who chose not to participate and why (only 20.7% included this), end of data collection justification (25.0% included this) and researcher bias (16.1% included this). The quantitative studies showed overall fair/good quality (9.2% of studies being assessed as good across categories and 65.9% being assessed as fair), with the exception of the ethics and bias category (49.3% assessed as poor and 12.7% assessed as very poor). Only 5.6% of studies were assessed as good quality in this category, which required papers to include explicit details regarding issues of patient confidentiality, sensitivity and informed consent. Researchers also were required to be reflexive or be aware of any potential bias they may have. One-third of studies (32.4%) acknowledged these issues without including explicit details; however, the majority either briefly mentioned them or did not include them (see supplementary material for further details, http://links.lww.com/QAD/B44).

Barriers

Forty-three unique patient-reported barriers were identified in 79 (90.8%) of the qualitative and 68 (95.8%) of the quantitative studies that we developed into nine themes comprising financial constraints, problems with their health provider and other interpersonal relationships, issues regarding medication collection and medication taking, treatment-related challenges, problems with their mental health and well-being and beliefs about HIV and treatment as well as specific beliefs about ART. See Table 1 for a list of the themes and both
Table 1. Barriers and facilitators.

| Themes                      | Barriers (n of studies that reported factor)                                      | Facilitators (n of studies that reported factor)                  |
|-----------------------------|---------------------------------------------------------------------------------|------------------------------------------------------------------|
| Financial                   | Lack of money for transport to ART clinic (32)                                 | Grant or livelihood support (5)‡                                  |
|                             | Lack of money for HIV care (19)                                                 | Free ART treatment (4)                                           |
|                             | Do not want to lose disability grant (6)                                        |                                                                  |
| Health provider             | Dissatisfaction with HIV/ART information provided (17)                         | Good relationship with health provider (22)§                      |
|                             | Experienced negative treatment from clinic staff (10)                           | Receiving counselling and/or teaching (17)                       |
|                             | Unable to gain attention from staff (9)                                         |                                                                  |
|                             | Poor relationship with health provider (5)                                       |                                                                  |
| Medication taking           | Forgetting (76)a                                                                | Reminders (55)                                                   |
|                             | Lack of access to adequate food (72)b,d                                        | Having a routine (9)                                            |
|                             | Stigma and discrimination (68)                                                  | ART packaging (7)                                               |
|                             | Outside house or travelling (60)d                                               | Access to food and/or water (6)‡                                 |
|                             | Being busy (30)                                                                | Carrying ART whilst out of the house (5)                         |
|                             | Run out of ART (26)                                                            |                                                                  |
|                             | Sleeping (22)                                                                  |                                                                  |
|                             | Difficulty taking ART in private (17)a                                          |                                                                  |
|                             | Change in daily routine (15)                                                   |                                                                  |
|                             | No access to liquids (6)a                                                      |                                                                  |
| Interpersonal relationships | Lack of social support (22)d                                                    | Social support (60)d§                                            |
|                             | Sharing or selling ART (7)                                                      | Having disclosed HIV status (26)d§                               |
|                             | HIV nondisclosure (21)d                                                        | Want to live and take care of children (21)                      |
|                             | Sex (wives have lack of autonomy) (6)                                           | Attending a support group (11)                                  |
|                             |                                                                 | Seeing others improve on ART (6)                                |
| Mental health and well being| Feeling sick or ill (30)d                                                       | Want to look healthy to others (5)                               |
|                             | Using alcohol or other substances (27)d                                         | Staying away from negative relationships (2)                     |
|                             | Feeling better or healthier (26)d                                               | Feeling better or healthier (35)d†                               |
|                             | Low mood or stress (22)d                                                       | Being able to work again (13)                                   |
|                             | Feeling hopeless (7)d                                                          | ‘Normalization’ – feeling the same as others or same as before HIV (8) |
|                             | Feeling lonely (4)                                                             | Fewer HIV/AIDS-related illnesses (8)                            |
| Beliefs about HIV and treatment| Religious beliefs or treatments (27)d                                          | Prayers or faith in God (8)                                     |
|                             | Traditional beliefs or medicines (20)                                           | Being hopeful (6)†                                               |
|                             | Fear of cause of HIV (6)                                                       |                                                                  |
|                             | Denial of HIV status (4)d                                                      |                                                                  |
| Beliefs about ART           | Negative attitude towards treatment regime (19)                                 | Belief in ART benefit (20)d§                                     |
|                             | ART will not work (7)d                                                         | Do not want to be ill again (14)                                 |
|                             | ART is harmful (7)                                                             | Adherence self-efficacy (8)                                     |
|                             | Lack of motivation to take ART (7)                                              | ART helps you look healthy to others (5)                        |
|                             | Should not mix ART with other treatments (4)                                   | God provided ART (4)                                            |
| Medication collection       | Erratic clinic drug supply (22)                                                 |                                                                  |
|                             | Long clinic waiting times (13)a                                                 |                                                                  |
|                             | Long distance to the clinic (8)                                                 |                                                                  |
|                             | Unable to get to clinic due to work constraints (7)                             |                                                                  |
| Treatment-related factors   | Side effects (67)c                                                             |                                                                  |
|                             | Pill burden (20)                                                               |                                                                  |
|                             | Problem with physical characteristics of pills (4)                             |                                                                  |

ART, antiretroviral treatment.

*a One mixed-methods study identified the barriers or facilitators in both the qualitative and quantitative components.
*b Three mixed-methods studies identified the barriers or facilitators in both the qualitative and quantitative components.
*c Two mixed-methods studies identified the barriers or facilitators in both the qualitative and quantitative components.
*d Comparable barriers and facilitators across themes.
*e Same factor as both a barrier and facilitator.
*f Same factor as well as a comparable factor to another barrier or facilitator.

eighty-seven percent of the qualitative and 21 (29.6%) of the quantitative studies. Seventeen facilitators (56.7%) were only identified in the qualitative studies. The facilitators are composed of seven of the same themes as the barriers.
excluding medication collection and treatment-related factors (see Table 1). Due to the comparable themes, the barriers and facilitators will be described together.

**Themes**

There were several factors that impacted adherence related to finance as well as each patient's health provider. Within the finance theme, in particular not receiving financial help was a barrier, whereas receiving funds was a benefit. Across studies, the fifth most reported facilitator was having a good relationship with their health provider \((n = 22)\). The opposite was identified as a barrier, however, only by a few studies \((n = 5)\).

Four of the five most-reported barriers across all studies were classified into the medication-taking theme; forgetting \((n = 76)\), lack of access to adequate food \((n = 72)\), stigma and discrimination \((n = 68)\) and being outside the house or travelling \((n = 60)\). Some of these had comparable facilitators, including having reminders to take medication [which was the second most reported facilitator \((n = 55)\)], having access to food or water and carrying ART whilst out of the house, although the latter two were only identified by a small number of studies.

Interpersonal relationships included the first and fourth most reported facilitators [social support \((n = 60)\) and having disclosed their HIV status \((n = 26)\)]. Both of these included comparable barriers (e.g. lack of social support and HIV nondisclosure) indicating that an absence of these factors is a barrier to adherence.

Mental health and well-being was the only theme to include the same factor as both a barrier and facilitator, feeling better or healthier after ART treatment. This factor was the third most reported facilitator across studies \((n = 35)\), although 26 studies also reported it as a barrier. Another comparable barrier to feeling better was also reported (feeling sick or ill) indicating that the opposite can also hinder adherence. Feeling hopeless and being hopeful were both reported as comparable factors, although only reported in a few studies.

The patients’ beliefs about HIV and treatments theme also included factors that acted as a barrier or facilitator. Both religious and traditional beliefs and treatments were indicated as a barrier to adhering to ART, whilst a patient’s desire to take control of their health was a facilitator. Denial of one’s own HIV status was reported as a barrier and had a comparable facilitator of accepting one’s own HIV status, although these were reported by a small number of studies. Specific beliefs about ART also showed to have an impact on adherence. The belief in the benefit of ART was reported \((n = 20)\) as a facilitator, whereas believing ART will not work was reported as a barrier, but only by seven studies in comparison.

Both medication collection and treatment-related factors only included barriers. The latter theme included the fourth most reported barrier across studies, side effects \((n = 67)\). Erratic clinic drug supply and long waiting times were reported by the most studies as a barrier to ART adherence in the medication collection theme.

**Discussion**

**Summary of evidence**

In this systematic review, a total of 43 patient-reported barriers and 30 facilitators to ART adherence were identified in 154 studies across 24 SSA countries. Barriers and facilitators to ART adherence included factors related to participants’ physically taking their ART medication (e.g. unable to take their pills without adequate food or using reminders to remember to take their pills), factors that impacted participants’ physical or mental health (e.g. feeling sick or feeling better after taking ART), factors related to participants’ relationships with other people (e.g. nondisclosure of HIV status to others or social support), factors related to finance (e.g. lack of money for HIV care or free ART treatment), factors related to participants’ health provider including all staff (e.g. experiencing negative treatment from clinic staff or having a good relationship with their health provider), beliefs around HIV and treatments for HIV (e.g. using traditional medicines or accepting own HIV status) and beliefs regarding ART (e.g. ART is harmful or ART is beneficial). Factors related to collecting medication at the clinic (e.g. long waiting times or erratic drug supply) and treatment-related factors (e.g. side effects or pill burden) were only reported as barriers to ART adherence. One factor was both a barrier and facilitator (e.g. feeling better after taking ART), which emphasizes medication-adhering behaviour is not universal and it is necessary to explore this individually. The most frequently identified barriers across studies and methodologies were forgetting, lack of access to adequate food, stigma and discrimination, side effects and being outside the house or travelling. The most frequently identified facilitators across studies and methods were social support, using reminders, feeling better or healthier after taking ART, disclosing their HIV status and having a good relationship with a health provider. This review helps identify the range and frequency of factors that impact ART adherence for patients within a variety of different settings in SSA.

Other systematic reviews have focused on specific types of adherence barriers, including geographic and transport-related barriers in SSA [171], food insecurity [172] and depression and alcohol use in SSA [173]. These reviews are useful because they go in-depth into one type of barrier and they may focus on HIV outcomes other than adherence [171]; however, this review is necessary to
Barriers and facilitators to antiretroviral therapy

Croome et al

Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.

give an overview of the many factors that affect ART adherence in SSA.

Frequency across studies does not necessarily equate with importance for individuals; therefore, the most reported factors may not have the greatest impact upon adherence. Unfortunately, the low number of studies that included the nonadherent within-study frequencies means it is difficult to compare the impact of these on adherence. Future studies should include these to allow researchers to ascertain not only the range of factors that affect adherence but also the impact of each.

This review identified 26 barriers that were not previously reported in SSA in the previous systematic review [3], including traditional medicines, religious beliefs or treatments, lack of access to food and sharing medication. These need to be acknowledged when working with people living with HIV in SSA. The five most frequently reported facilitators were included in the previous review [3], showing that there is similarity between patients in HIC and LMIC; however, several others were identified that had not been previously noted, for example financial aid, access to food and water and religious beliefs. This further confirms that there are factors that may be more applicable to LMIC that therefore need particular consideration when designing interventions to improve ART adherence.

Understanding and being aware of these are important for policy makers, researchers and health professionals. Although patients denied missing ART doses to their health professional, if a barrier measure was used, patients would then reveal nonadherence by indicating the barriers that prevent them from adhering [174]. Having a list of barriers that are applicable to the context is essential. There are some differences between HIC and LMIC and this should be reflected in the provisions available for patients. Although general and HIV-specific measures for barriers to adherence do currently exist [175–179], none encompass the wide range of reasons identified in this review. Developing or adapting a measure that can be utilized by health professionals in SSA is necessary. In particular, the most commonly used self-report HIV adherence measure [180] (Adult AIDS Care Trials Group [AACTG]) includes a 'reasons for non-adherence' subscale [175] that needs to be adapted if used in SSA to include all relevant factors. To our knowledge, there is not a similar measure for facilitators and research needs to explore whether assessing the facilitators may be equally as helpful as the barriers to reach the level of desired adherence.

Immediate treatment initiation after diagnosis has been shown to have more positive HIV outcomes than later [181,182] and thus may become the recommended start date globally. There are debates in the literature about the practicalities associated with immediate ART initiation [183], including increased burden on the healthcare system, increased frequency of risk behaviours when receiving ART and ethical issues such as resource allocation in low-resource settings [183]. The impact of certain barriers may increase, such as the factors associated with healthcare; therefore, the need to enhance the facilitators will become greater.

Future research needs to help identify the barriers and facilitators that have the greatest impact on adherence and help develop interventions based upon these. Within SSA, there have been several interventions focused on helping participants remember their medication, whereas less have focused on lack of food or stigma [184]. Research needs to explore whether these other interventions would have a greater influence on adherence. In addition, the focus on adherence interventions in SSA has often been observational and more randomized control trials (RCTs) are required [184].

Limitations

Although efforts were made to include all eligible studies, it is possible that not all studies exploring barriers and facilitators to ART adherence in SSA were included, as research from resource-constrained settings may be less likely to be published or not indexed in the major databases [185]. The studies are not easily compared due to the heterogeneity of how factors and adherence were measured. There was a great variety of within-study frequency measurement; therefore, only studies that included the frequency of reporting within nonadherent participants were included. Also, some studies combined separate factors into one, so it was not possible to extract the individual factors. The quality of the studies seemed generally fair; however, there were areas of poor quality. As two measures were utilized in quality assessment, it is not easy to compare the quality across both qualitative and quantitative studies.

The majority of the qualitative studies identified both barriers and facilitators, whereas the majority of the quantitative studies only identified barriers. This bias may have prevented certain facilitators from being identified. Barrier measures or adapted versions [175,177,186–189] were utilized in some surveys that may have caused certain barriers to be reported more frequently; however, other important barriers may have been missed because they were not included.

Conclusion

This review highlights the range and frequency of barriers and facilitators that affect ART adherence in HIV adult patients in SSA. Research needs to help identify which factors have the greatest impact on adherence and develop interventions accordingly. Measures need to be developed or adapted for SSA to include all the relevant factors. Interventions need to be developed that aim to reduce the barriers and enhance the facilitators. By understanding...
and being able to identify what hinders a patient experiences and how certain aspects may encourage them to adhere, the focus is now on using this information to help patients achieve optimum ART outcomes.

Acknowledgements

N.C. drafted the protocol including the search strategy and L.D.H and M.Ah. helped develop the final one. N.C. performed the electronic search. N.C. and M.Ah. identified and quality assessed relevant studies. N.C. wrote the first draft. All authors contributed to subsequent drafts. All authors read and approved the final draft. Open access for this article was funded by King’s College London.

Conflicts of interest

There are no conflicts of interest.

References

1. Joint United Nations Programme on HIV/AIDS (UNAIDS). The Cap report. Geneva: UNAIDS; 2014, http://www.unaids.org/sites/default/files/media_asset/UNAIDS_Cap_report_en.pdf.
2. World Health Organisation (WHO). Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Geneva: World Health Organisation; 2013, http://www.who.int/hiv/pub/guidelines/en/.
3. Mills EJ, Nachega JB, Bangsberg DR, Singh S, Rachlis B, Wu P, et al. Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Med 2006; 3:e438.
4. Hardon AP, Akurat D, Comoro C, Ekezie C, Irunde HF, Gerrits T, et al. Hunger, waiting time and transport costs: time to confront challenges to ART adherence in Africa. AIDS Care 2007; 19:658–663.
5. Orrell C, Bangsberg DR, Radri M, Wood R. Adherence is not a barrier to successful antiretroviral therapy in South Africa. AIDS 2003; 17:1369–1375.
6. Bangsberg DR. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis 2006; 43:939–941.
7. Mills EJ, Nachega JB, Buchan I, Orbinski J, Attaran A, Singh S, et al. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA 2006; 296:679–690.
8. Ojikutu B, Makadzange AT, Gaolathe T. Scaling up ART treatment capacity: lessons learned from South Africa, Zimbabwe, and Botswana. Curr HIV/AIDS Rep 2008; 5:94–98.
9. Mayston R, Kinyanda E, Chishonga N, Prince M, Patel V. Mental disorder and the outcome of HIV/AIDS in low-income and middle-income countries: a systematic review. AIDS 2012; 26:S117–S135.
10. Langbeek N, Gisolf EH, Reiss P, Vervoort SC, Thóra B, Richter C, et al. Predictors and correlates of adherence to combination antiretroviral therapy (cART) for chronic HIV infection: a meta-analysis. BMC Med 2014; 12:142.
11. Merten S, Kenter E, McKenzie O, Musheke M, Ntashla H, Martin-Hilber A. Patient-reported barriers and drivers of adherence to antiretrovirals in sub-Saharan Africa: a meta-ethnography. Trop Med Int Health 2010; 15:11–17.
12. Molter D, Libaerti A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009; 151:264–269.
13. Leamy M, Bird V, Le Bourdillier C, Williams J, Slade M. Conceptual framework for personal recovery in mental health: systematic review and narrative synthesis. Br J Psychiatry 2011; 199:445–452.
14. Slade M, Leamy M, Bacon F, Janosik M, Le Bourdillier C, Williams J, et al. International differences in understanding recovery: systematic review. Epidemiol Psychiatr Sci 2012; 21:353–364.
15. Clark J. How to peer review a qualitative manuscript. Peer Rev Sci 2003; 2:219–235.
16. Hawker S, Payne S, Kerr C, Hardy M, Powell J. Appraising the evidence: reviewing disparate data systematically. Qual Health Res 2002; 12:1284–1299.
17. Aransiola J, Iroanya W, Obewowoere S, Orosumo A. Low adherence to HIV/AIDS in Nigeria: stigma and survival challenges preventing optimum benefit from an ART clinic. Glob Health Promot 2014; 21:3–22.
18. Arem H, Nakajano N, Kagaya J, Mulambja I, Nakigozi G, Serwadda D, et al. Peer health workers and AIDS care in Rakai, Uganda: a mixed methods operations research evaluation of a cluster-randomized trial. AIDS Patient Care STDS 2011; 25:719–724.
19. Asgary R, Antony S, Grigoryan Z, Aronson J. Community perception, misconception, and discord regarding prevention and treatment of infection with human immunodeficiency virus in Addis Ababa, Ethiopia. Ann J Trop Med Hygiene 2014; 90:153–159.
20. Aspeling HE, van Wyk NC. Factors associated with adherence to antiretroviral therapy for the treatment of HIV-infected women attending an urban care facility. Int J Nurs Pract 2008; 14:3–10.
21. Audu B, Morgan R, Rutter P. Qualitative exploration of the relationship between HIV/AIDS patients’ experiences of clinical services and treatment adherence at Maitama District Hospital, Abuja, Nigeria. AIDS Care 2014; 26:270–273.
22. Avelsson JM, Hallager S, Bartolos TS. Antiretroviral therapy adherence strategies used by patients of a large HIV clinic in Lesotho. J Health Popul Nutr 2015; 33:10.
23. Baghazali AA. Factors influencing adherence to antiretroviral therapy at a general hospital in Mombasa, Kenya [Master’s thesis]. University of the Western Cape; 2011. http://hdl.handle.net/11394/2570.
24. Balcha TT, Jeppsson A, Bekele A. Barriers to antiretroviral treatment in Ethiopia: a qualitative study. J Int Assoc Phys AIDS Care 2011; 10:119–125.
25. Beyene KA, Gedef G, Gebre-Mariam T, Engidawork E. Highly active antiretroviral therapy adherence and its determinants in selected hospitals from south and central Ethiopia. Pharmacoeconomic Drug Saf 2009; 18:1007–1015.
26. Bezabhe WM, Chalmers L, Bereznicki LR, Peterson GM, Birnrew MA, Kassie DM. Barriers and facilitators of adherence to antiretroviral drug therapy and retention in care among adult HIV-positive patients: a qualitative study from Ethiopia. PLoS One 2014; 9:e97353.
27. Bhagwanjee A, Govender K, Akintola O, Petersen I, George G, Johnstone L, Naidoo K. Patterns of disclosure and antiretroviral treatment adherence in a South African mining workplace programme and implications for HIV prevention. Afr J AIDS Res 2011; 10:291–391.
28. Boateng D, Kwakong GD, Agyei-Baffour P. Knowledge, perception about antiretroviral therapy (ART) and prevention of mother-to-child-transmission (PMTCT) and adherence to ART among HIV positive women in the Ashanti Region, Ghana: a cross-sectional study. BMC Women’s Health 2013; 13:2.
29. Bohle LF, Dilger H, Groß U. HIV-serostatus disclosure in the context of free antiretroviral therapy and socio-economic dependency: experiences among women living with HIV in Tanzania. Afr J AIDS Res 2014; 13:215–227.
30. Byron E, Gillespie S, Nangami M. Integrating nutrition security with treatment of people living with HIV: lessons from Kenya. Food Nutr Bull 2008; 29:87–97.
31. Campbell C, Scott K, Skovdal M, Madanire C, Nyamukapa C, Gregson S. A good patient? How notions of ‘a good patient’ affect patient-nurse relationships and ART adherence in Zimbabwe. BMC Infect Dis 2015; 15:404.
32. Chileshe M, Bond VA. Barriers and outcomes: TB patients co-infected with HIV accessing antiretroviral therapy in rural Zambia. AIDS Care 2010; 22:51–59.
The experience of 'medicine companions': Patient-nominated, community-based HIV treatment supporters: patient perspectives, feasibility, challenges, and factors for success in HIV-infected South African adults. *AIDS Pat Care STDs* 2013; 27:96–102.

Elwell K. Facilitators and barriers to treatment adherence within PMTCT programs in Malawi. *AIDS Care* 2016; 28:971–975.

Foster SD, Nakamanya S, Kyomuhangi R, Amurwon J, Namara G, Amuron B, et al. The experience of ‘medicine companions’ to support adherence to antiretroviral therapy: quantitative and qualitative data from a trial population in Uganda. *AIDS Care* 2010; 22:35–43.

Frank J, Duncan N. Speaking to experts and patients: recommendations for improving antiretroviral therapy (ART) adherence. *Health Soc Care Community* 2009; 17:37–45.

Gachanja G, Burkholder GJ. A model for HIV disclosure of a parent’s and/or a child’s illness. *Peer J* 2016; 4:e1662.

Goudge J, Ngoma B. Exploring antiretroviral treatment adherence in an urban setting in South Africa. *J Public Health Policy* 2011; 32:S52–S64.

Govender V, Fried J, Rollo K, Chimbini N, Cleary S. Disability Grant: a precarious lifeline for HIV/AIDS patients in South Africa. *AIDS Service Deliv Rev* 2015; 17:226–237.

Grant E, Logie D, Masura M, Gorman D, Murray SA. Factors facilitating and challenging access and adherence to ART: a qualitative study in a township in the Zambian Copperbelt. *AIDS Care* 2008; 20:1153–1160.

Gusdal AK, Obua C, Andualem T, Wahlstrom R, Tomson G, Petersen MG, et al. Voices on adherence to ART in Ethiopia and Uganda: a matter of choice or simply not an option? *AIDS* 2009; 21:1381–1387.

Hussen SA, Tesfaye M, Argaw MG, Andes K, Gilliard D, del Rio C, Spaulding, social capital and service: factors promoting or hindering resilience among Expert Patients living with HIV in Ethiopia. *Global Public Health* 2014; 9:286–298.

Izughara CO, Wekesa E. Beliefs and practices about antiretroviral medication: a study of poor urban Kenyans living with HIV/AIDS. *Soc Health Illness* 2011; 33:869–883.

Jones C. ‘If I take my pills I’ll go hungry’: the choice between economic security and HIV/AIDS treatment in Grahamstown, South Africa. *Ann Anthrop Pract* 2011; 35:67–80.

Karanja SW. Factors influencing adherence to antiretroviral Medications among patients living with HIV in Kenya [Master’s thesis]. University of Nairobi, 2013. http://eerepository.uonbi.ac.ke/handle/11295/60397 [Accessed 25 May 2016].

Khaliq FI. Adherence to antiretroviral therapy and associated factors among HIV and AIDS patients at Minazi Mmoja Hospital, Zanzibar [Master’s thesis]. 2012. http://141.204.187.24:8080/handle/123456789/1010 [Accessed 25 May 2016].

Kidia K, Machando D, Bere T, Macpherson K, Nyamwara P, Potter L, et al. ‘I was thinking too much’: experiences of HIV-positive adults with common mental disorders and poor adherence to antiretroviral therapy in Zimbabwe. *Trop Med Int Health* 2015; 20:903–913.

Kutesa MO, Seeley J, Cumming RG, Negin J. Older people living with HIV in Uganda: understanding their experience and needs. *Afr J AIDS Res* 2012; 11:293–305.

Foster SD, Nakamanya S, Kyomuhangi R, Amurwon J, Namara G, Amuron B, et al. Experience of ‘medicine companions’ to support adherence to antiretroviral therapy: quantitative and qualitative data from a trial population in Uganda. *AIDS Care* 2010; 22:35–43.

Frank J, Duncan N. Speaking to experts and patients: recommendations for improving antiretroviral therapy (ART) adherence. *Health Soc Care Community* 2009; 17:37–45.

Gachanja G, Burkholder GJ. A model for HIV disclosure of a parent’s and/or a child’s illness. *Peer J* 2016; 4:e1662.

Goudge J, Ngoma B. Exploring antiretroviral treatment adherence in an urban setting in South Africa. *J Public Health Policy* 2011; 32:S52–S64.

Govender V, Fried J, Rollo K, Chimbini N, Cleary S. Disability Grant: a precarious lifeline for HIV/AIDS patients in South Africa. *AIDS Service Deliv Rev* 2015; 17:226–237.

Grant E, Logie D, Masura M, Gorman D, Murray SA. Factors facilitating and challenging access and adherence to ART: a qualitative study in a township in the Zambian Copperbelt. *AIDS Care* 2008; 20:1153–1160.

Gusdal AK, Obua C, Andualem T, Wahlstrom R, Tomson G, Petersen MG, et al. Voices on adherence to ART in Ethiopia and Uganda: a matter of choice or simply not an option? *AIDS* 2009; 21:1381–1387.

Hussen SA, Tesfaye M, Argaw MG, Andes K, Gilliard D, del Rio C, Spaulding, social capital and service: factors promoting or hindering resilience among Expert Patients living with HIV in Ethiopia. *Global Public Health* 2014; 9:286–298.

Izughara CO, Wekesa E. Beliefs and practices about antiretroviral medication: a study of poor urban Kenyans living with HIV/AIDS. *Soc Health Illness* 2011; 33:869–883.

Jones C. ‘If I take my pills I’ll go hungry’: the choice between economic security and HIV/AIDS treatment in Grahamstown, South Africa. *Ann Anthrop Pract* 2011; 35:67–80.

Karanja SW. Factors influencing adherence to antiretroviral Medications among patients living with HIV in Kenya [Master’s thesis]. University of Nairobi, 2013. http://eerepository.uonbi.ac.ke/handle/11295/60397 [Accessed 25 May 2016].

Khaliq FI. Adherence to antiretroviral therapy and associated factors among HIV and AIDS patients at Minazi Mmoja Hospital, Zanzibar [Master’s thesis]. 2012. http://141.204.187.24:8080/handle/123456789/1010 [Accessed 25 May 2016].

Kidia K, Machando D, Bere T, Macpherson K, Nyamwara P, Potter L, et al. ‘I was thinking too much’: experiences of HIV-positive adults with common mental disorders and poor adherence to antiretroviral therapy in Zimbabwe. *Trop Med Int Health* 2015; 20:903–913.

Kutesa MO, Seeley J, Cumming RG, Negin J. Older people living with HIV in Uganda: understanding their experience and needs. *Afr J AIDS Res* 2012; 11:293–305.

Foster SD, Nakamanya S, Kyomuhangi R, Amurwon J, Namara G, Amuron B, et al. Experience of ‘medicine companions’ to support adherence to antiretroviral therapy: quantitative and qualitative data from a trial population in Uganda. *AIDS Care* 2010; 22:35–43.
Field adherence to highly active antiretroviral therapy (cART) in Botswana. *AIDS Res Hum Retroviruses* 2010; 26:685–691.

Dyrehave C, Rasmussen DN, Henge BL, Jespersen S, Correia FG, Medina C, et al. Nonadherence is associated with lack of HIV-related knowledge: a cross-sectional study among HIV-infected individuals in Guinea-Bissau. *Int Assoc Provid AIDS Care* 2016; 15:350–358.

Ebu-H. Yehwo H, Alemaayehu M. Level of adherence and predictors of adherence to the Option B + PHTMCT programme in Tigray, northern Ethiopia. *Int Infect Dis* 2015; 33:123–129.

Eholie SP, Tanou A, Polneau S, Ouimling M, Djadjé A, Kangah-Koffi C, et al. Field adherence to highly active antiretroviral therapy in HIV-infected adults in Abidjan, Cote d’Ivoire. *J Acquir Immune Defic Syndr* 2007; 45:355–358.

Elul B, Basinga P, Nwagwagwa-Birimbomwaho H, Saito S, Horowitz D, Nash D, et al. High levels of adherence and viral suppression in a nationally representative sample of HIV-infected adults on antiretroviral therapy for 6, 12 and 18 months in Rwanda. *PloS One* 2013; 8:e53586.

Essomba EN, Adigbo D, Koum DC, Amang B, Lehan LM, Coppieters Y. [Factors associated with nonadherence of adults infected with HIV on antiretroviral therapy in a referral hospital in Douala]. *Pan Afr Med J* 2013; 20:112.

Eyassu MA. Adherence to antiretroviral therapy among HIV and AIDS patients at the Kwa-Thema Clinic in the Gauteng Province, South Africa [Master’s thesis]. University of Limpopo; 2015. http://ulspace.ul.ac.za/handle/10386/1218 [Accessed 25 May 2016].

Garang PG, Odoi RA, Kalyango JN. Adherence to antiretroviral therapy in conflict areas: a study among patients receiving treatment from Lacer Hospital, Uganda, *AIDS Patient Care STDs* 2009; 23:743–747.

Georgette N, Siedner MJ, Zanoni B, Siyaba T, Petty CR, Carpenter S, et al. The acceptability and perceived usefulness of a weekly clinical SMS program to promote high antiretroviral medication adherence in Kwazulu-Natal, South Africa. *AIDS Behav* 2016; 20:2629–2638.

Goar SG, Audu MD, Aagbir M, Matalaw B. Substance abuse and adherence to antiretroviral therapy among patients attending clinic at a specialist hospital in Jos, Nigeria. *Afr J Drug Alcohol Studes* 2015; 14:37–47.

Guiru AK, Traore A, Somda A, Huang SL. Attitudes and practices towards HAART among people living with HIV/AIDS in a resource-limited setting in northern Burkina Faso. *Public Health* 2011; 125:784–790.

Habib AG, Abduhumanni M, Dalhat MM, Hamza M, Ilyasu G. Anti-retroviral therapy among HIV infected travelers to Hajj Pilgrimage. *J Travel Med* 2010; 17:176–181.

Hong SY, Fanelli TJ, Jonas A, Gweshe J, Tijuka F, Sheehan HM, et al. Household food insecurity associated with antiretroviral therapy adherence among HIV-infected patients in Windhoek, Namibia. *J Acquir Immune Defic Syndr* 2014; 67:e113–e122.

Jaquet A, Ekouevi DK, Bashi J, Aboahblakrine M, Messou E, Maiga MV. Alcohol use and nonadherence to antiretroviral therapy in HIV-infected patients in West Africa. *Addiction* 2010; 105:1416–1421.

Jenekh et al. Poor adherence to treatment of people living with HIV/AIDS [Master’s thesis], University of Stellenbosch; 2011. http://scholar.sun.ac.za/handle/10019.1/6848 [Accessed 25 May 2016].
AIDS 2017, Vol 31 No 7

145. Oku AO, Owoja ET, Ige OK, Oyo-Ita A. Prevalence and determinants of adherence to HAART amongst PLHIV in a tertiary health facility in south-south Nigeria. BMC Infect Dis 2013;13:401.

146. Oku AO, Owoja ET, Oku OD, Monjok E. Prevalence and determinants of adherence to highly active antiretroviral therapy amongst people living with HIV/AIDS in a rural setting in south-south Nigeria. Afr J Reprod Health 2014; 18:133–143.

147. Omole MK. Adisa R. Investigation of factors affecting medication adherence among people living with HIV/AIDS under Nongovernmental organization in Ibadan city, Nigeria. J Pharm Biom Sci 2012; 21:1–5.

148. Onyango DO. Barriers to antiretroviral treatment adherence among HIV infected tuberculosis patients in Jaramogi Oginga Odinga Teaching and Referral Hospital Kisumu, Kenya [Master’s thesis], University of Nairobi, 2013. http://repository.ounb.ac.ke/handle/11295/56548 [Accessed 25 May 2016].

149. Oumar AA, Dao S, Diamoutene A, Coulibaly S, Kounarme B, Maiga II, et al. [Factors associated with antiretroviral treatment observance at Point ‘G’ hospital] [French]. Le Mali Med 2007; 22:18–21.

150. Oyore J, Mwanzo I, Orago A, Odhiambo-Otieno G. Determinants of adherence to antiretroviral therapy (ART) among patients attending public and private health facilities in Nairobi, Kenya. J AIDS HIV Res Vol 2013; 5:70–74.

151. Pefu-Rayne EW, Soh E, Kengne AP, Baltssou AD, KuaBan C. Nonadherence to antiretroviral therapy in Yaounde: prevalence, determinants and the concordance of two screening criteria. J Infect Public Health 2013; 6:307–315.

152. Peltzer K, Preez NF, Ramlagan S, Fornum H, Anderson J. Traditional complementary and alternative medicine and antiretroviral treatment adherence among HIV patients in KwaZulu-Natal, South Africa. Afr J Tradit Complement Altern Med 2010; 7:125–137.

153. Petchoo Y, Tchamjda K, Balogou A, Pichre VP, Guissou IP, Kassang EK. Factors influencing adherence to antiretroviral medication in Cotonou, Benin. J Int Assoc Physicians AIDS Care 2010; 9:191–195.

154. Salami AK, Fadeyi A, Ogunmodede JA, Desalu O. Factors influencing adherence to antiretroviral medication in Ilorin, Nigeria. J Int Assoc Physicians AIDS Care 2010; 9:191–195.

155. Sam OB. Factors that constrain adherence to antiretroviral therapy among HIV positive patients in the Sekondi-Takoradi Metropolitan [Master’s thesis]. Kwame Nkrumah University of Science and Technology, Ghana; 2015. http://ir.knust.edu.gr/handle/123456789/7724 [Accessed 25 May 2016].

156. Sasaki Y, Kakimoto K, Dube C, Sikazwe I, Moyo C, Syakantu W, Zwickl B, et al. Factors associated with nonadherence to highly active antiretroviral therapy amongst people living with HIV/AIDS in a rural setting in south-south Nigeria. Afr J Reprod Health 2014; 18:133–143.

157. Tsega B, Srikanth BA, Shewamene Z. The development of an inventory to evaluate of antiretroviral therapy adherence: a review with recommendations for HIV research and clinical management. AIDS Care 2014; 26:136–140.

158. Tadehse S, Tadese A, Wubshet M. Adherence to antiretroviral treatment and associated factors among people living with HIV/AIDS in Northwest Ethiopia. J Trop Dis 2014; 2:1000133.

159. Amankeah AK. Facilitators and barriers to antiretroviral therapy adherence among HIV/AIDS patients: a multi-case study of Sunyani regional and municipal hospitals [Master’s thesis]. University of Ghana; 2015. http://ugspace.ug.edu.gh/handle/123456789/8158 [Accessed 25 May 2016].

160. Jones D, Zulu I, Mumbi M, Chitalu N, Vamos S, Gomez J, et al. Strategies for living with the challenges of HIV and antiretroviral use in Zambia. Int J Ecol Health Educ 2009; 12:1–18.

161. Lankowski AJ, Siedner MJ, Bangsberg DR, Tsi AC. Impact of geographic and transportation-related barriers on HIV outcomes in sub-Saharan Africa: a systematic review. AIDS Behav 2014; 18:1199–1223.

162. Singer AW, Weiser SD, McCoy SI. Does food insecurity undermine adherence to antiretroviral therapy? A systematic review. AIDS Behav 2015; 19:1510–1526.

163. Simoni JM, Kurth AE, Pearson CR, Pantalone DW, Merrill JO, Frick PA. Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.
181. Group ISS. Initiation of antiretroviral therapy in early asymptomatic HIV infection. *N Engl J Med* 2013; 2015: 795–807.

182. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. *N Engl J Med* 2011; 365:493–505.

183. Kulkarni SP, Shah KR, Sarma KV, Mahajan AP. Clinical uncertainties, health service challenges, and ethical complexities of HIV ‘test-and-treat’: a systematic review. *Am J Public Health* 2013; 103: e14–e23.

184. Barnighausen T, Chaiyachati K, Chimbindi N, Peoples A, Haberer J, Newell ML. Interventions to increase antiretroviral adherence in sub-Saharan Africa: a systematic review of evaluation studies. *Lancet Infect Dis* 2011; 11:942–951.

185. Govindasamy D, Ford N, Kranzer K. Risk factors, barriers and facilitators for linkage to antiretroviral therapy care: a systematic review. *AIDS* 2012; 26:2059–2067.

186. Catz SL, Kelly JA, Bogart LM, Benotsch EG, McAuliffe TL. Patterns, correlates, and barriers to medication adherence among persons prescribed new treatments for HIV disease. *Health Psychol* 2000; 19:124.

187. Coetzee B, Kagee A. The development of an inventory to assess the structural barriers to clinic attendance and pill-taking amongst users of antiretroviral therapy. *AIDS Behav* 2013; 17:319–328.

188. The LifeWindows Project Team. The LifeWindows Information Motivation Behavioral Skills ART Adherence Questionnaire (LW-IMB-AAQ) Center for Health, Intervention, and Prevention. University of Connecticut; 2006. http://chipcontent.chip.uconn.edu/chipweb/documents/Research/F_LWIMBARTQuestionnaire.pdf [Accessed 30 May 2016].

189. Svarstad BL, Chewning BA, Sleath BL, Claesson C. The Brief Medication Questionnaire: a tool for screening patient adherence and barriers to adherence. *Patient Educ Couns* 1999; 37:113–124.